Goldman Sachs analyst Christopher Merwin upgraded ReneSola to Buy from Neutral with a price target of $180, up from $147. The shares closed Friday down $1.78 to $149.22. After a "strong" fiscal Q3 report, the analyst sees "several catalysts" for Splunk shares to positively re-rate over the next 12 months. These include a new pricing model that decouples revenue from indexed log volume, newly-reported annual recurring revenue growth, and "de-risked" cash flow expectations through fiscal 2023. For a company that is growing annual recurring revenue over 50%, and should continue to grow at least mid-40% through next year per management guidance, Splunk's current valuation of eight-times 2020 sales is "undemanding," Merwin tells investors in a research note.

New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).